Cymabay Therapeutics, Inc. is a biopharmaceutical company based in Newark, California, focused on developing innovative therapies for metabolic diseases. The company specializes in addressing intrahepatic cholestatic diseases, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hyperuricemia, and gout treatment. Utilizing advanced research in heterocyclic receptor agonists and oxymethylene aryl compounds, Cymabay aims to provide effective solutions for patients suffering from various metabolic disorders.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

43 Patents

#11 in Newark, CA

#1,901 in California

#8,099 in US

#16,040 in the World

Newark, CA, United States of America

Cymabay Therapeutics, Inc.

Forward Citations = 120

41 inventors:

Charles A McWherter (32 out of 33 patents)

Brian K Roberts (15 out of 16 patents)

Pol Boudes (13 out of 14 patents)

4. Jiangao Song (10 out of 24 patents)

5. David Brian Karpf (10 out of 16 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Cymabay Therapeutics, Inc.. Retrieved from https://idiyas.com/company/cymabay-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

6 patents (CIPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

14 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]